Trials / Available
AvailableNCT05959239
TB006 Expanded Access (EA) Compassionate Use
Expanded Access With TB006 Treatment in Adults With Alzheimer's Disease and Related Dementias
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- TrueBinding, Inc. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- —
Summary
This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.
Detailed description
A participant's physician who is interested in participating in this program will need to go to the company's website for further information and application forms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TB006 | TB006 will be provided as single-use injectable glass vials. |
Timeline
- First posted
- 2023-07-25
- Last updated
- 2024-12-09
Source: ClinicalTrials.gov record NCT05959239. Inclusion in this directory is not an endorsement.